Sangam Health Care Products Ltd

Sangam Health Care Products Ltd has announced the closure of its trading window from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's code of conduct. All designated persons and their immediate relatives are prohibited from trading in the company's securities during this period. The date for the board meeting to approve these financial results will be communicated separately.

Sangam Health Care Products Ltd's board meeting on May 29, 2026, approved the audited financial results for the quarter and financial year ended March 31, 2026. The board also approved the auditor's report with an unmodified opinion for the same period. The meeting commenced at 3:00 P.M. (IST) and concluded at 3:50 P.M. (IST).

Sangam Health Care Products Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026, along with the audit report for the same period. The meeting will also address any other business with the permission of the Chair.

Sangam Health Care Products Ltd has announced the closure of its trading window for dealing in the securities of the company. The closure will be in effect from 1st April, 2026, and will reopen after 48 hours from the declaration of audited financial results for the quarter and year ending 31.03.2026. The decision is in accordance with the Company's minimum Standards Code of Conduct and the SEBI (Prohibition of Insider Trading) Regulations.

Sangam Health Care Products Ltd has announced the resignation of its Chief Financial Officer (CFO), Mr. Satish Kumar Varre, due to personal reasons. He will be relieved from his duties on February 24, 2026. The company has expressed its appreciation for his services and contributions during his tenure.

Sangam Health Care Products Ltd has appointed Mrs. S Vijayagowri Satya Bhavani as the Chief Financial Officer and Key Managerial Personnel (KMP) of the Company, with effect from February 24th, 2026. Mrs. Bhavani has over 15 years of experience in the field of Finance and Accounting and has been handling finance related matters for the company for the past 10 years. She holds a B Com degree from Andhra University, Hyderabad. The appointment is in accordance with provisions of Section 203 of the Companies Act, 2013 and SEBI Listing Regulations.

Sangam Health Care Products Ltd announced the appointment of Mrs. S Vijayagowri Satyabhavani as the new Chief Financial Officer (CFO) and accepted the resignation of Mr. Satish Kumar Varre from the same position. The board meeting held on 24.02.2026 approved these changes. Mrs. S Vijayagowri Satyabhavani has over 15 years of experience in Finance and Accounting and has been with the company for the past 10 years. Mr. Satish Kumar Varre resigned due to certain professional responsibilities and personal reasons.

Sangam Health Care Products Ltd has announced that a meeting of the Board of Directors will be held on 24th February 2026. The agenda includes the appointment of a new Chief Financial Officer in compliance with the Companies (Appointment and Qualification of Directors) Rules, 2014 and the Companies (Meetings of Board and its Powers) Regulations, 2015. The meeting will also consider any other business with the permission of the Chair.

Sangam Health Care Products Ltd, a manufacturer and seller of medical disposables and surgical products, has reported its un-audited financial results for the quarter and nine months ended 31.12.2025. The results were reviewed by the Audit Committee and taken on record by the Board of Directors. The company is operating in only one business segment, and all figures are un-audited except for the year ended 31.03.2025. The Limited Review of the Financials has been carried out by the Statutory Auditors of the Company.

Sangam Health Care Products Ltd. announced its unaudited financial results for the quarter and nine months ended 31.12.2025. The company's revenue from operations stands at ₹ 50,05,36,350 for Q3 and ₹ 91,13,20,038 for the nine-month period. The net profit for Q3 is ₹ 3,10,52,050 and ₹ 6,26,22,073 for the nine-month period. The company operates in the manufacturing and sale of medical disposables and surgical products segment.